National Institute on Drug Abuse (NIDA)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute on Drug Abuse (NIDA) sits in the top decile of US sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count).
National Institute on Drug Abuse (NIDA): 335 sponsored US clinical trials, 14 recruiting.
National Institute on Drug Abuse (NIDA) sponsors 335 registered US clinical trials on ClinicalTrials.gov, 14 of them currently recruiting, and 292 completed. 30 of these trials are in Phase 3-4 (later-stage) and 202 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cocaine-Related Disorders, with 17 trials.
Top-decile sponsor footprint
National Institute on Drug Abuse (NIDA) ranks in the top decile of sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
292 of 316 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
335 total, page 6 of 7
Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5
NCT00015223
Buprenorphine Detoxification - BBDVI - 19
NCT00000237
Stress Hormones and Human Cocaine Use - 7
NCT00000290
Tyrosine for Methamphetamine Dependence - 1
NCT00000322
Modeling Impaired Judgement in Cocaine Abusers - 6
NCT00015236
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
NCT00158288
Tryptophan and Behavior Therapy for Cocaine Abuse - 1
NCT00000324
Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9
NCT00000274
Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety
NCT00004373
Prepulse Inhibition of Startle in Cocaine Dependence - 7
NCT00015249
Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users
NCT00158236
Cocaine Effects in Humans: Physiology and Behavior - 1
NCT00000200
Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3
NCT00000286
Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1
NCT00000352
Buprenorphine and Naloxone Combination Study - 10
NCT00015288
Cocaine Abuse and ADHD - 10
NCT00000275
Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2
NCT00015041
Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1
NCT00015028
Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1
NCT00000315
Trial of Buprenorphine/Naloxone for Opiate Dependence - 2
NCT00000353
Methamphetamine Abuse Treatment in Patients With AIDS - 1
NCT00000321
Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2
NCT00000316
Evaluation of Liquid vs. Tablet Buprenorphine - 6
NCT00000341
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
NCT00134914
Therapeutic Potential of Kappa-Opioids Against Cocaine - 1
NCT00000323
Risperidone for the Treatment of Cocaine Dependence - 7
NCT00000342
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3
NCT00000354
Effects of Phenytoin on Cocaine Use in Humans - 2
NCT00000285
Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1
NCT00015171
Acute Withdrawal From Smoked Cocaine - 9
NCT00000292
Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10
NCT00000345
Brain Changes in Stimulant Dependent Subjects - 8
NCT00000343
Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2
NCT00000310
Role of Metabolites in Nicotine Dependence (2) - 5
NCT00000288
Pergolide Treatment for Substance Abusers - 4
NCT00000269
Activity Monitoring Assessment of Opiate Withdrawal - 4
NCT00000335
Dextroamphetamine-Cocaine Behavioral Intervention - 5
NCT00000308
Buprenorphine Combination Tablet Feasibility - 1
NCT00000298
Cocaine Abuse and Attention Deficit Disorder - 3
NCT00000268
Naltrexone in Treatment of Cocaine Dependence - 5
NCT00015080
Role of Metabolites in Nicotine Dependence (1) - 1
NCT00000284
Relapse Patterns in Female Cocaine Users - 4
NCT00000287
Selegiline in Outpatient Treatment for Cocaine Dependence - 1
NCT00000336
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
NCT00000318
Alternate-Day Buprenorphine Administration. Phase VII - 8
NCT00000226
Infusion Laboratory: Protocol 1 - Selegeline - 2
NCT00000337
Effects of Buprenorphine and Naloxone in Opiate Addicts - 4
NCT00000355
M-CPP and Fenfluramine in Cocaine Addicts - 3
NCT00000314
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
NCT00000306
Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1
NCT00000266
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 81 |
| Phase 2 | 121 |
| Phase 3 | 14 |
| Phase 4 | 16 |
What is open in the National Institute on Drug Abuse (NIDA) pipeline
14 recruiting of 335 indexed (4% open); 292 completed (87%).
Phase mix: 30 late (III/IV) vs 202 early (I/II) (early-phase heavy).
Top condition: Cocaine-Related Disorders (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute on Drug Abuse (NIDA): open-pipeline peers nationwide
Peers matched on 335 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
National Institute on Drug Abuse (NIDA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 335 trials (± recruiting share)
- Biogen · 334 trials · 6% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Genentech · 332 trials · 7% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Akebia Therapeutics · 4% recruiting · 24 trials
- Dentsply Sirona Implants and Consumables · 4% recruiting · 24 trials
- Smith & Nephew · 4% recruiting · 72 trials
- Medtronic - MITG · 4% recruiting · 119 trials
Related
What to do with this National Institute on Drug Abuse (NIDA) page
335 registered trials is a research-attention snapshot, not an endorsement of National Institute on Drug Abuse (NIDA) or any single study.
- 14 of National Institute on Drug Abuse (NIDA)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cocaine-Related Disorders is the condition National Institute on Drug Abuse (NIDA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cocaine-Related Disorders trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute on Drug Abuse (NIDA) pipeline card: 335 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.